SAUDI ARABIA Trends and Developments Contributed by: Saud Alromi, Mostafa Ihab, Mohamed Ramadan and Saleh Albadry, Mohammed AlDhabaan & Partners Eversheds Sutherland
Mohammed Al Dhabaan & Partners Eversheds Sutherland Offices 9-10-11 Home Offices PO Box 245555
Riyadh 11312 Saudi Arabia
Tel: +966 11 277 9800 Fax: +966 11 281 6611 Email: DAPESprojects@aldhabaan-es.com Web: www.aldhabaan-es.com
Regulatory Environment The Saudi Food and Drug Authority (SFDA) plays a crucial role in regulating the pharmaceutical industry in Saudi Arabia. The SFDA ensures drug safety, effi ‑ cacy and quality through stringent pharmacovigilance measures. All pharmaceutical products must receive SFDA approval before entering the Saudi market. The SFDA provides comprehensive guidelines to assist manufacturers in registering their products, including bioequivalence studies for generic drugs and clinical trials for vaccines. The SFDA’s guidelines on bioequivalence studies for generic drugs and clinical trials for vaccines are criti ‑ cal for ensuring drug safety and efficacy. These guide ‑ lines provide a clear framework for manufacturers to follow, reducing the likelihood of rejected applications and facilitating market entry. The SFDA’s approach to developing guidelines involves public consulta ‑ tion, allowing stakeholders to provide feedback and ensuring that the guidelines are comprehensive and practical. The Saudi Authority for Intellectual Property (SAIP) is another key regulatory body, responsible for protect ‑ ing and enforcing intellectual property (IP) rights in the Kingdom. Established in 2018, SAIP oversees patent registrations, trade marks and copyrights, ensuring alignment with international standards. SAIP aims to regulate, support, develop, sponsor, protect, enforce and upgrade the fields of IP in Saudi Arabia in accord ‑ ance with international best practices, and it is organi ‑ sationally linked to the Prime Minister.
SAIP’s role in protecting IP rights is equally impor ‑ tant. SAIP ensures that patents are granted for new and innovative pharmaceutical products, providing a period of market exclusivity that allows companies to recoup their investment and fund future research. SAIP also plays a crucial role in enforcing IP rights, taking legal action against infringers and ensuring that counterfeit products are removed from the market. Pricing rules The SFDA has detailed rules for pricing pharmaceu ‑ tical products, taking into account factors such as therapeutic value, prices of alternatives and economic studies. Key points include: • innovative and biological products – priced based on export prices and comparative studies; • generic products – priced at a percentage of the innovative product’s price, with reductions as more generics enter the market; and • re-pricing – products may be re-priced based on market conditions, therapeutic class reviews and company requests. SFDA guidelines The SFDA has established comprehensive guidelines for the submission, validation, assessment and pricing of pharmaceutical products. These guidelines ensure drug safety, efficacy and quality through stringent pharmacovigilance measures. Key aspects include: • bioequivalence studies – required for generic drugs to ensure they meet safety and efficacy standards;
210 CHAMBERS.COM
Powered by FlippingBook